Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Open access
Uprety, Dipesh, Mandrekar, Sumithra J., Wigle, Dennis, Roden, Anja C., Adjei, Alex A.·2020·Journal of Thoracic Oncology

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Patients with resectable non-small cell lung cancer (NSCLC) are often treated with surgery and adjuvant chemotherapy. However, these patients continue to have a high risk of recurrence and death. Unfortunately, there has been little progress in the treatment of resectable NSCLC over the last several decades. Neoadjuvant therapy, which has been considered an approach to improve survival for resectable NSCLC patients, is a hotly debated topic. A systematic review of 32 randomized trials involving 10,000 patients demonstrated that there was no difference in survival between pre and post-operative chemotherapy. Because of such results, and the theoretical concern about resectable tumors progressing on relatively ineffective neoadjuvant chemotherapy and thus becoming unresectable, neoadjuvant chemotherapy fell out of favor and many clinicians preferred adjuvant chemotherapy post-surgery. Neoadjuvant therapy has however been revived in the last couple of years following emerging data from various ongoing trials suggesting that neoadjuvant immunotherapy may have significant efficacy and could potentially improve survival of patients with resectable NSCLC. In this review article, we discuss the evidence supporting the role of neoadjuvant immunotherapy in the multimodality management of resectable NSCLC. We summarize early results of ongoing clinical trials, and highlight the challenges in adopting a uniform definition of treatment "success." We address hurdles to be overcome in order to seek regulatory approval for neoadjuvant immunotherapy and establish it as a standard of care. Finally we provide some perspectives for the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.05.020

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 201

Metadata

Authors
Uprety, D., Mandrekar, S. J., Wigle, D., Roden, A. C., & Adjei, A. A.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2020-08
Volume
15
Issue
8
Pages
1281-1297
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3033779930
Cited by
201
References
19
FWCI
15.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. https://app.cochat.ai/papers/10.1016/j.jtho.2020.05.020
The paper
Uprety, D., Mandrekar, S. J., Wigle, D., Roden, A. C., & Adjei, A. A. (2020). Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.05.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.